Abstract
Reduced cellular immune function in patients after liver transplantation easily results in many types of viral infections, such as Epstein-Barr virus. Epstein-Barr virus is a Γ-herpesvirus and is related to many malignant diseases, especially epithelial and lymph tumors. The abnormal interaction of cluster of differentiation 40 with cluster of differentiation 40 ligand and expression of cluster of differentiation 40 ligand are considered closely related to the development of myeloma cells. This study explored the influence and mechanism of Epstein-Barr virus infection on the phenotype and biological behavior of myeloma cells after liver transplantation. Flow cytometry was used to detect coexpression of cluster of differentiation 40 and cluster of differentiation 40 ligand in 10 samples of freshly isolated multiple myeloma cells. Cluster of differentiation 40 and cluster of differentiation 40 ligand were coexpressed in sample Nos. 5, 8, 9, and 10, particularly in sample No. 5. Western blot analysis was used to detect the expression of the Epstein-Barr virus antigens latent membrane protein 1 and Epstein-Barr virus nuclear antigen 2 in the multiple myeloma cell line RPMI 8226 infected with Epstein-Barr virus. The antigen expression indicated that Epstein-Barr virus can infect multiple myeloma virus cells in vitro. Reverse transcription-polymerase chain reaction revealed upregulated expression of cluster of differentiation 40 ligand on the infected RPMI 8226 cells, which may be involved in the anti-apoptosis activity of the infected cells. Confocal microscopy showed that pairs of molecules of cluster of differentiation 40, cluster of differentiation 40 ligand, and latent membrane protein 1 were colocalized on the surface of the infected cells. CXC chemokine receptor 4 was upregulated on the RPMI 8226 cells after Epstein-Barr virus infection. The migratory ability of the infected cells improved in the presence of the chemokine stromal cell-derived factor-1α. Anti-apoptosis and migration are known important biological characteristics of malignant cells. Our results indicate the involvement of Epstein-Barr virus in the origin and development of multiple myeloma. The risk of multiple myeloma increases when Epstein-Barr virus infects B cells in the germinal center, which may result in an anti-apoptosis effect of B cells and an improved ability to migrate from the germinal center to peripheral blood.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Berenson J R, Vescio R A. HHV-8 is present in multiple myeloma patients. Blood, 1999, 93: 3157–3159
Bishop G A, Hostager B S. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev, 2003, 14: 297–309
Busch L K, Bishop G A. The EBV transforming protein, LMP1, mimics and cooperates with CD40 signaling in B lymphocyte. J Immunol, 1999, 162: 2555–2561
Cacciarelli T V, Green M, Jaffe R, et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation, 1998, 66: 1047–1052
Challa A, Eulopulos A G, Holder M J, et al. Population depletion activates autonomous CD154-dependent survival in biopsy-like Burkitt’s lymphoma cells. Blood, 2002, 99: 3411–3418
Clodi K, Asgary Z, Zhao S, et al. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol, 1998, 103: 270–275
Fuleihan R, Ramesh N, Horner A, et al. Cyclosporin A inhibits CD40 ligand expression in T lymphocytes. J Clin Invest, 1994, 93: 1315–1320
Hallek M, Bergsagel P L, Anderson K C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 1998, 91: 3–21
Hanissian S H, Geha R S. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity, 1997, 6: 379–387
Imadome K, Shirakata M, Shimizu N, et al. CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation. Proc Natl Acad Sci USA, 2003, 100: 7836–7840
Kaykas A, Worringer K, Sugden B. CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex. EMBO J, 2001, 20: 2641–2654
Oh H M, Oh J M, Choi S C, et al. An efficient method for the rapid establishment of Epstein-Barr virus immortalization of human B lymphocytes. Cell Prolif, 2003, 36: 191–197
Larsen C P, Elwood E T, Alexander D Z, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature, 1996, 381: 434–438
Arcipowski K M, Stunz L L, Graham J P, et al. Molecular mechanisms of TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral mimic of CD40, latent membrane protein 1 (LMP1). J Biol Chem, 2011, 286: 9948–9955
Wang Z, Yang S, Zhou L, et al. Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination. Sci China Life Sci, 2011, 54: 263–266
Mathur R K, Awasthi A, Wadhone P, et al. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med, 2004, 10: 540–544
Mutimer D, Kaur N, Tang H, et al. Quantification of Epstein-Barr virus DNA in the blood after adult liver transplantation. Transplantation, 2000, 69: 954–959
Nalesnik M A, Rao A S, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation, 1997, 63: 1200–1205
Xu H, Zhao G, Huang X, et al. CD40-expressing plasmid induces anti-CD40 antibody and enhances immune responses to DNA vaccination. J Gene Med, 2010, 12: 97–106
Qi C J, Zheng L, Zhou X, et al. Cross-linking of CD40 using anti-CD40 antibody, 5C11, has different effects on XG2 multiple myeloma cells. Immunol Lett, 2004, 93: 151–158
The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Hematol, 2003, 121: 749–757
Tong A W, Seamour B, Chen J, et al. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leuk Lymphoma, 2000, 36: 543–558
Uchida J, Yasui T, Takaoka-Shichijo Y, et al. Mimicry of C40 signals by EBV LMP1 in B lymphocyte responses. Science, 1999, 286: 300–303
Young L S, Rickinson A B. Epstein-Barr virus: 40 years on. Nat Rev Cancer, 2004, 4: 757–768
Zimber-Strobl U, Kempkes B, Marschall G, et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J, 1996, 15: 7070–7078
Cao J, Shen C, Zhang J, et al. Comparison of alternative extraction methods for secretome profiling in human hepatocellular carcinoma cells. Sci China Life Sci, 2011, 54: 34–38
Author information
Authors and Affiliations
Corresponding author
Additional information
Contributed equally to this work
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Zhang, Y., Zhao, H., He, X. et al. Effects of Epstein-Barr virus infection on the development of multiple myeloma after liver transplantation. Sci. China Life Sci. 55, 735–743 (2012). https://doi.org/10.1007/s11427-012-4362-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-012-4362-3